Nivolumab (Opdivo) and Pembrolizumab (Keytruda)

Type: drug

Status: FDA Approved

Developer: Bristol Myers Squibb (Nivolumab) and Merck (Pembrolizumab)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026